Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

Jonathan W. Friedberg; Andres Forero-Torres; Beata Holkova; Jerome H. Goldschmidt; Ralph V. Boccia; Rodolfo Bordoni; Vivian Jean M. Cline; Dipti Patel-Donnelly; Patrick J. Flynn; Gregg A. Olsen; Robert W. Chen; Faith Galderisi; Yinghui Wang; Jeff Porter Sharman; Christopher A. Yasenchak

doi:10.1200/JCO.2018.36.15_SUPPL.7542

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

Jonathan W. Friedberg
, Andres Forero-Torres
, Beata Holkova
, Jerome H. Goldschmidt
, Ralph V. Boccia
, Rodolfo Bordoni
, Vivian Jean M. Cline
, Dipti Patel-Donnelly
, Patrick J. Flynn
, Gregg A. Olsen
, Robert W. Chen
, Faith Galderisi
, Yinghui Wang
, Jeff Porter Sharman
, Christopher A. Yasenchak

University of Rochester Medical Center
University of Alabama at Birmingham
VCU Medical Center
Oncology and Hematology Assoc of SW Virginia, Blacksburg, VA;
Center for Cancer and Blood Disorders, Bethesda, MD;
Georgia Cancer Specialists, Marietta, GA;
Texas Oncology
Virginia Cancer Specialists, Fairfax, VA;
Minnesota Oncology, Minneapolis, MN;
Providence St Joseph Medical Center, Burbank, CA;
City of Hope National Medical Center
Seattle Genetics
Willamette University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	36
DOIs	https://doi.org/10.1200/JCO.2018.36.15_SUPPL.7542
State	Published - Jun 1 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2018.36.15_SUPPL.7542License: Unspecified

Cite this

Friedberg, J. W., Forero-Torres, A., Holkova, B., Goldschmidt, J. H., Boccia, R. V., Bordoni, R., Cline, V. J. M., Patel-Donnelly, D., Flynn, P. J., Olsen, G. A., Chen, R. W., Galderisi, F., Wang, Y., Sharman, J. P., & Yasenchak, C. A. (2018). Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. Journal of Clinical Oncology, 36. https://doi.org/10.1200/JCO.2018.36.15_SUPPL.7542

Friedberg, JW, Forero-Torres, A, Holkova, B, Goldschmidt, JH, Boccia, RV, Bordoni, R, Cline, VJM, Patel-Donnelly, D, Flynn, PJ, Olsen, GA, Chen, RW, Galderisi, F, Wang, Y, Sharman, JP & Yasenchak, CA 2018, 'Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.', Journal of Clinical Oncology, vol. 36. https://doi.org/10.1200/JCO.2018.36.15_SUPPL.7542

@article{2dc9b4fd5a5640d48a6ea812746d6e25,

title = "Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.",

author = "Friedberg, \{Jonathan W.\} and Andres Forero-Torres and Beata Holkova and Goldschmidt, \{Jerome H.\} and Boccia, \{Ralph V.\} and Rodolfo Bordoni and Cline, \{Vivian Jean M.\} and Dipti Patel-Donnelly and Flynn, \{Patrick J.\} and Olsen, \{Gregg A.\} and Chen, \{Robert W.\} and Faith Galderisi and Yinghui Wang and Sharman, \{Jeff Porter\} and Yasenchak, \{Christopher A.\}",

note = "7542 Background: Elderly patients (pts) with Hodgkin lymphoma (HL) have few treatment (tx) options and poor outcomes compared to younger pts. This phase 2, frontline, open-label trial studied brentuximab vedotin monotherapy (BV; ADCETRIS) and BV+dacarbazine (DTIC) in these pts (NCT01716806).",

year = "2018",

month = jun,

day = "1",

doi = "10.1200/JCO.2018.36.15\_SUPPL.7542",

language = "American English",

volume = "36",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

AU - Friedberg, Jonathan W.

AU - Forero-Torres, Andres

AU - Holkova, Beata

AU - Goldschmidt, Jerome H.

AU - Boccia, Ralph V.

AU - Bordoni, Rodolfo

AU - Cline, Vivian Jean M.

AU - Patel-Donnelly, Dipti

AU - Flynn, Patrick J.

AU - Olsen, Gregg A.

AU - Chen, Robert W.

AU - Galderisi, Faith

AU - Wang, Yinghui

AU - Sharman, Jeff Porter

AU - Yasenchak, Christopher A.

N1 - 7542 Background: Elderly patients (pts) with Hodgkin lymphoma (HL) have few treatment (tx) options and poor outcomes compared to younger pts. This phase 2, frontline, open-label trial studied brentuximab vedotin monotherapy (BV; ADCETRIS) and BV+dacarbazine (DTIC) in these pts (NCT01716806).

PY - 2018/6/1

Y1 - 2018/6/1

UR - https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.7542

U2 - 10.1200/JCO.2018.36.15_SUPPL.7542

DO - 10.1200/JCO.2018.36.15_SUPPL.7542

M3 - Article

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

Disciplines

Access to Document

Other files and links

Cite this